OOIR: Observatory of International Research

Papers

(The TQCC of Gut is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts. The publications cover those that have been published in the past four years, i.e., from 2019-03-01 to 2023-03-01.)

Article	Citations
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults	878
Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms	821
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial	415
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis	411
Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates: a prospective randomised controlled study	400
Gut commensal Parabacteroides goldsteinii plays a predominant role in the anti-obesity effects of polysaccharides isolated from Hirsutella sinensis	375
Real-time differentiation of adenomatous and hyperplastic diminutive colorectal polyps during analysis of unaltered videos of standard colonoscopy using a deep learning model	366
Leaky gut: mechanisms, measurement and clinical implications in humans	355
Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy	346
METTL3-mediated m⁶A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance	338
Role of the microbiome in human development	326
Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years	318
Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma	309
Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial	305
Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries	295
Global patterns and trends in colorectal cancer incidence in young adults	287
Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites	266
Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus	251
Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium	246
Major microbiota dysbiosis in severe obesity: fate after bariatric surgery	240
Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study	230
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial	228
Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model	223
British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma	221
Interaction between drugs and the gut microbiome	219
Epidemiology of chronic liver diseases in the USA in the past three decades	213
Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer	213
Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice	211
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer	209
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites	208
Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial	205
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice	203
Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study	202
Gut mucosal virome alterations in ulcerative colitis	200
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?	191
A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8⁺ T cells in mice	187
Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin	183
Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease	182
Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens	181
Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake	180
Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis	178
Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and sys	177
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study	173
Randomised controlled trial of WISENSE, a real-time quality improving system for monitoring blind spots during esophagogastroduodenoscopy	171
Non-superiority of lumen-apposing metal stents over plastic stents for drainage of walled-off necrosis in a randomised trial	171
Inflammatory bowel disease increases the risk of Parkinson’s disease: a Danish nationwide cohort study 1977–2014	167
Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study	162
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade	162
Liver organoids: from basic research to therapeutic applications	159
Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis	158
Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis	156
Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas	155
Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Canc	154
Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma	152
Human gastric cancer modelling using organoids	152
Impact of characteristics of organ failure and infected necrosis on mortality in necrotising pancreatitis	151
British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines	148
Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management	146
Single-cell RNAseq reveals seven classes of colonic sensory neuron	146
Treatment with camu camu (Myrciaria dubia) prevents obesity by altering the gut microbiota and increasing energy expenditure in diet-induced obese mice	143
Alterations of gut microbiome in autoimmune hepatitis	143
Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer	141
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus	139
Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents	137
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial	136
Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection	133
International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis	132
Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time	132
Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression	131
Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology	129
Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review	128
Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035	127
Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice	127
Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma	126
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease	126
Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity	125
Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study	125
Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes	122
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome	122
Tight junction proteins in gastrointestinal and liver disease	119
British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis	117
Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?	117
A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer	116
Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer	115
Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer	114
Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD	113
Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression	111
Participation and yield of a population-based colorectal cancer screening programme in China	111
Microbiota fermentation-NLRP3 axis shapes the impact of dietary fibres on intestinal inflammation	108
Albumin in decompensated cirrhosis: new concepts and perspectives	108
Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations	106
miRNAs and NAFLD: from pathophysiology to therapy	105
Endosonography-guided gallbladder drainage versus percutaneous cholecystostomy in very high-risk surgical patients with acute cholecystitis: an international randomised multicentre controlled superior	105
Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis	104
Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota	104
Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients	104
Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility	103
Muscle-derived cell injection to treat anal incontinence due to obstetric trauma: pilot study with 1 year follow-up	103
A blood-based prognostic biomarker in IBD	103
STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis	103
Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis	101
Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study	99
Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease	98
Novel concepts in the pathophysiology and treatment of functional dyspepsia	97
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study	97
Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial	96
Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis	95
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)	95
Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes	95
Computer-aided diagnosis using deep learning in the evaluation of early oesophageal adenocarcinoma	94
Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension	94
Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS Lost trial	94
Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn’s disease: results from two large prospective cohort studies	93
Gastroparesis: a turning point in understanding and treatment	92
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis	92
Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma	92
DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development	92
Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease	91
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan	91
New artificial intelligence system: first validation study versus experienced endoscopists for colorectal polyp detection	90
Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients	90
Identification of TMAO-producer phenotype and host–diet–gut dysbiosis by carnitine challenge test in human and germ-free mice	90
Real-time use of artificial intelligence in the evaluation of cancer in Barrett’s oesophagus	89
Gut dysbiosis induces the development of pre-eclampsia through bacterial translocation	89
Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice	89
Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing	88
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges	88
Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load	88
Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report	88
Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year afterHelicobacter pylorieradication	88
Circulating microbiome in blood of different circulatory compartments	88
IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology	87
Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study	87
Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study	86
Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis	86
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning	85
Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)	85
Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study	85
Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma	84
Faecal virome transplantation decreases symptoms of type 2 diabetes and obesity in a murine model	83
Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome	82
Impairment of spermatogenesis and sperm motility by the high-fat diet-induced dysbiosis of gut microbes	82
Lactobacillus rhamnosusGG protects the intestinal epithelium from radiation injury through release of lipoteichoic acid, macrophage activation and the migration of mesenchymal stem cells	81
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer	81
Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma	80
Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma	80
Myristoleic acid produced by enterococci reduces obesity through brown adipose tissue activation	80
Big data in IBD: big progress for clinical practice	80
Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis	78
Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease	78
SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer	77
Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study	76
Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct st	76
Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989–2012: a matched case–control study	75
Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study	75
Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis	75
Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances	74
Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study	74
Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis	74
An Asian consensus on standards of diagnostic upper endoscopy for neoplasia	74
Improved adenoma detection with Endocuff Vision: the ADENOMA randomised controlled trial	72
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives	72
Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study	72
High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity	71
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans	71
Role of brain imaging in disorders of brain–gut interaction: a Rome Working Team Report	70
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab	70
Evolutionary history of human colitis-associated colorectal cancer	70
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?	69
Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting	68
Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription	68
Antibiotic and acid-suppression medications during early childhood are associated with obesity	68
Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose	68
Microbiota and cancer immunotherapy: in search of microbial signals	68
USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation	68
Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions	68
Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection	68
β-catenin-activated hepatocellular carcinomas are addicted to fatty acids	66
Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling	65
Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels	65
Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage	65
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial	64
Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer	64
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion	63
Efficacy of endoscopic screening for esophageal cancer in China (ESECC): design and preliminary results of a population-based randomised controlled trial	63